Kuros Biosciences Net Income From Continuing Ops Over Time
| KURN Stock | CHF 25.24 0.24 0.96% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kuros Biosciences Performance and Kuros Biosciences Correlation. Kuros |
Cross Equities Net Income From Continuing Ops Analysis
Compare Kuros Biosciences and related stocks such as Idorsia, SKAN Group AG, and COSMO Pharmaceuticals Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDIA | (336.7 M) | (336.7 M) | (336.7 M) | (336.7 M) | (336.7 M) | (336.7 M) | (336.7 M) | (18.3 M) | (387.5 M) | (494.6 M) | (445.1 M) | (634.6 M) | (827.9 M) | (374.1 M) | (263.8 M) | (237.4 M) | (249.3 M) |
| SKAN | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 21.4 M | 21.4 M | 27.9 M | 40.8 M | 46.9 M | 27.1 M |
| COPN | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 248.2 M | 19.3 M | (32.4 M) | (18.1 M) | (24.5 M) | (7.9 M) | 21.7 M | 17.5 M | (4.7 M) | 133.2 M | 119.9 M | 125.9 M |
| AEVS | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 3.7 M | 2.7 M | 1.1 M | (6.6 M) | 173.7 M | (30.9 M) | 4.6 M | 61.8 M | (41.9 M) | (8.3 M) | (7.5 M) | (7.1 M) |
| BSLN | (41.5 M) | (41.5 M) | (41.5 M) | (41.5 M) | (41.5 M) | (61.6 M) | (51.3 M) | (19.4 M) | (31.4 M) | (22.4 M) | (14.7 M) | (6.8 M) | 12.1 M | 10.5 M | 77.6 M | 89.2 M | 93.7 M |
| MED | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 3.3 M | 866.5 K | 4.2 M | 2.1 M | (943.6 K) | 6.8 M | (5.8 M) | 620 K | 3.5 M | 3.2 M | 1.8 M |
| PPGN | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 25.7 M | 31.3 M | 47.3 M | 7.8 M | (51.4 M) | (19.6 M) | (17.6 M) | (16.7 M) |
| BION | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 652.8 M | (802.1 M) | 687.5 M | (471.3 M) | 677.4 M | 691.2 M | (404.8 M) | (357.8 M) | (206.6 M) | 75.9 M | 68.3 M | 64.9 M |
| NWRN | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (22.8 M) | (15.2 M) | (5.3 M) | (15 M) | (20.2 M) | (21 M) | (14.9 M) | (17.5 M) | (16.2 M) | 15.8 M | 18.2 M | 19.1 M |
Kuros Biosciences and related stocks such as Idorsia, SKAN Group AG, and COSMO Pharmaceuticals Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Kuros Biosciences AG | KURN |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | Wagistrasse 25, Schlieren, |
| Exchange | SIX Swiss Exchange |
CHF 25.24
Additional Tools for Kuros Stock Analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.